The Vaccine 2026 Conference, scheduled for October 05–06, 2026, in Paris, France, is an international scientific forum focused on advancing vaccine research, clinical development, and immunization practices. The conference will bring together researchers, clinicians, public health professionals, scientists, and industry experts to examine current challenges and future directions in vaccinology.

With the theme “Precision Vaccinology and Personalized Immunization Strategies,” the program will emphasize data-driven and population-specific approaches to vaccine design, evaluation, and delivery. Key discussions will cover next-generation vaccine platforms, immune profiling, biomarkers of vaccine response, translational research, and the integration of precision medicine into immunization programs. The conference aims to support scientific exchange, encourage collaboration, and promote evidence-based strategies that strengthen vaccination outcomes and global public health.

Why Attend?

Participating in the Vaccine Conference 2026 offers a unique opportunity for professionals in vaccinology, immunology, and public health to:

1. Gain insights into the latest research, technologies, and innovations in vaccine development and immunization.
2. Explore cutting-edge platforms, delivery systems, and strategies shaping the future of vaccines.
3. Network with leading scientists, clinicians, policymakers, and industry experts from around the world.
4. Earn continuing education credits and support professional growth and expertise.
5. Engage in interactive sessions, panel discussions, and collaborative workshops to exchange ideas.
6. Stay informed on emerging infectious diseases, immunization strategies, and global vaccine initiatives.

Target Audience

1. Vaccine researchers and scientists
2. Immunologists and microbiologists
3. Clinicians and healthcare professionals
4. Public health experts and epidemiologists
5. Regulatory authorities and policymakers
6. Pharmaceutical and biotechnology industry professionals
7. Clinical trial specialists and laboratory personnel
8. Vaccine manufacturing and production experts
9. Academicians and students in vaccinology, microbiology, and public health
10. Global health organizations and NGO representatives

Scientific Sessions and Tracks

Track 1: Vaccine Immunology

This track focuses on the immunological principles underlying vaccine-induced protection. It explores how innate and adaptive immune responses are activated by vaccines and how immune memory is established and maintained. Sessions will address antigen recognition, immune correlates of protection, adjuvant mechanisms, and host factors influencing vaccine efficacy. Emphasis will be placed on translating immunological insights into improved vaccine design, effectiveness, and safety across diverse populations.

Vaccine Immunology | Vaccine-Induced Immunity | Innate Immune Response | Adaptive Immunity | Humoral Immunity | Cellular Immunity | Immune Memory | Correlates of Protection | Antigen Presentation | Adjuvants | Immune Modulation

Track 2: Therapeutic and Cancer Vaccines

This track focuses on the development and clinical application of therapeutic vaccines designed to treat established diseases, including cancer. It highlights advances in tumor antigens, immune-based therapies, personalized vaccine approaches, and strategies to enhance antitumor immune responses. Sessions will address translational research, clinical trials, and emerging technologies shaping therapeutic vaccination.

Therapeutic Vaccines | Cancer Vaccines | Tumor Antigens | Cancer Immunotherapy | Personalized Vaccines | Neoantigen Vaccines | Immune Checkpoint Modulation | Cellular Immune Response | Therapeutic Immunization

Track 3: Global Vaccine Initiatives

This track focuses on international efforts to improve vaccine access, coverage, and equity. It highlights strategies for implementing immunization programs, policy development, public health planning, and collaborative efforts to control vaccine-preventable diseases worldwide. Sessions will cover lessons from large-scale vaccination campaigns, global partnerships, and strategies to reach underserved populations.

Global Vaccines | Immunization Programs | Vaccine Access | Vaccine Equity | Public Health Policy | Vaccination Campaigns | Vaccine Implementation | Disease Prevention | Global Health Initiatives | Vaccine Partnerships | Pandemic Preparedness

Track 4: Next-Gen Vaccine Research

This track focuses on cutting-edge approaches in vaccine development, including novel platforms, advanced antigen design, and innovative delivery systems. Discussions will cover mRNA vaccines, viral vectors, nanoparticle technologies, and strategies to improve immunogenicity and safety. Emphasis will be placed on translating scientific discoveries into next-generation vaccines for emerging and re-emerging infectious diseases.

Next-Generation Vaccines | Vaccine Innovation | mRNA Vaccines | Viral Vector Vaccines | Nanoparticle Vaccines | Antigen Design | Vaccine Platforms | Immunogenicity | Vaccine Safety | Emerging Infectious Diseases

Track 5: Maternal, Child & Elderly Vaccines

This track focuses on vaccination strategies for vulnerable populations, including infants, children, pregnant women, and the elderly. It covers age-specific immunization schedules, maternal immunization, booster strategies, and approaches to enhance vaccine coverage and protection in high-risk groups.

Pediatric Vaccines | Maternal Vaccines | Geriatric Vaccines | Age-Specific Immunization | Maternal Immunization | Infant Vaccination | Child Immunization | Elderly Vaccination | Booster Vaccines | High-Risk Populations

Track 6: Vaccine Delivery

This track focuses on innovative methods and devices for vaccine administration, including needle-free systems, micro-needle patches, oral formulations, and advanced delivery platforms. Discussions will cover strategies to improve vaccine stability, efficacy, accessibility, and patient compliance.

Vaccine Delivery | Delivery Systems | Needle-Free Vaccines | Microneedle Patches | Oral Vaccines | Advanced Vaccine Platforms | Vaccine Administration | Vaccine Stability | Immunization Technology | Patient Compliance | Innovative Delivery Methods

Track 7: Needle-Free Vaccines

This track focuses on non-invasive vaccine delivery methods that eliminate the use of needles. It includes mucosal, oral, intranasal, transdermal, and microneedle approaches. Sessions will cover strategies to improve patient compliance, vaccine stability, immune response, and accessibility for mass immunization programs.

Needle-Free Vaccines | Non-Invasive Vaccines | Mucosal Vaccines | Oral Vaccines | Intranasal Vaccines | Transdermal Vaccines | Microneedle Delivery | Vaccine Administration | Immunization Strategies | Patient Compliance

Track 8: Veterinary and Animal Health Vaccines

This track focuses on the development and application of vaccines for livestock, pets, and wildlife. It covers disease prevention, immunization strategies, vaccine safety, and emerging technologies to protect animal health and support food security.

Veterinary Vaccines | Animal Health Vaccines | Livestock Immunization | Pet Vaccines | Wildlife Vaccines | Disease Prevention | Vaccine Safety | Immunization Strategies | Emerging Animal Vaccines | Food Security | Zoonotic Disease Prevention

Track 9: Drug-Resistant Pathogen Vaccines

This track focuses on the development and evaluation of vaccines targeting drug-resistant bacterial, viral, and fungal pathogens. It highlights strategies to prevent infections, reduce antimicrobial resistance, and improve global health outcomes. Sessions will cover novel vaccine platforms, immune responses, and translational approaches to combat resistant pathogens.

Drug-Resistant Vaccines | Antimicrobial Resistance | Resistant Pathogen Vaccines | Bacterial Vaccines | Viral Vaccines | Fungal Vaccines | Vaccine Development | Immune Response | Infection Prevention | Translational Vaccinology | Global Health

Track 10: Vaccine Production & Scale-Up

This track focuses on the processes involved in manufacturing vaccines at clinical and commercial scale. Topics include bioprocess development, upstream and downstream processing, quality control, technology transfer, and strategies for efficient and reliable large-scale vaccine production.

Vaccine Production | Scale-Up Manufacturing | Bioprocess Development | Upstream Processing | Downstream Processing | Quality Control | Process Optimization | Technology Transfer | GMP Manufacturing | Vaccine Supply Chain

Track 11: AI-Driven Vaccine Design

This track focuses on the application of artificial intelligence and machine learning to accelerate vaccine discovery and development. It covers computational modeling, antigen prediction, immune response analysis, and data-driven approaches that support efficient and targeted vaccine design.

AI in Vaccinology | Machine Learning | Computational Vaccine Design | Antigen Prediction | Immunoinformatics | Data-Driven Research | Vaccine Discovery | Predictive Modeling | Bioinformatics | Systems Vaccinology

Track 12: Vaccine Safety and Pharmacovigilance

This track addresses the monitoring and evaluation of vaccine safety throughout development and post-licensure use. Topics include adverse event assessment, risk management, surveillance systems, and the use of real-world data to support safe and effective immunization programs.

Vaccine Safety | Pharmacovigilance | Adverse Events | Post-Licensure Surveillance | Risk Assessment | Safety Monitoring | Real-World Evidence | Vaccine Regulation | Signal Detection | Public Health Safety | Immunization Programs

Track 13: Multi-Antigen Vaccines

This track focuses on vaccines designed to target multiple antigens or pathogens within a single formulation. It covers strategies for antigen selection, formulation design, immune response optimization, and clinical evaluation to improve protection and streamline immunization schedules.

Multi-Antigen Vaccines | Combination Vaccines | Multivalent Vaccines | Antigen Selection | Vaccine Formulation | Immune Response | Broad-Spectrum Protection | Immunogenicity | Clinical Evaluation | Vaccine Development

Track 14: Vaccines for Pandemic Response

This track focuses on strategies for rapid vaccine development, evaluation, and deployment during infectious disease outbreaks. It covers platform technologies, emergency clinical trials, regulatory pathways, and coordinated responses to emerging public health threats.

Pandemic Vaccines | Outbreak Response | Rapid Vaccine Development | Emergency Vaccines | Emerging Infectious Diseases | Platform Technologies | Clinical Evaluation | Regulatory Pathways | Global Health Response

Track 15: Temperature-Stable Vaccines

This track focuses on vaccine formulations and technologies designed to maintain stability and efficacy under variable temperature conditions. Topics include formulation strategies, stabilization techniques, and approaches that reduce reliance on cold chain systems to improve vaccine access and distribution.

Thermostable Vaccines | Heat-Stable Vaccines | Vaccine Stability | Cold Chain Reduction | Formulation Science | Stabilization Technologies | Temperature Tolerance | Vaccine Storage | Distribution Efficiency | Global Immunization

Track 16: Biomarkers in Vaccine Development

This track focuses on the identification and application of biomarkers to assess vaccine efficacy, safety, and immune responses. It covers immune correlates of protection, predictive markers, and analytical tools that support vaccine design, clinical evaluation, and regulatory decision-making.

Vaccine Biomarkers | Correlates of Protection | Immune Markers | Vaccine Efficacy | Safety Assessment | Immunogenicity | Predictive Biomarkers | Clinical Evaluation | Translational Research | Vaccine Development

Track 17: Vaccine Regulatory Science

This track addresses the regulatory frameworks and scientific principles guiding vaccine development, evaluation, and approval. Topics include regulatory requirements, clinical trial oversight, quality standards, and post-approval monitoring to ensure vaccine safety, efficacy, and compliance.

Vaccine Regulatory Science | Regulatory Frameworks | Vaccine Approval | Clinical Trial Oversight | Quality Standards | Regulatory Compliance | Post-Approval Monitoring | Safety Evaluation | Vaccine Policy | Global Regulations

Track 18: Vaccinology and Genomics

This track focuses on the integration of genomic and systems-level data to inform vaccine discovery and evaluation. Topics include pathogen genomics, host genetic factors, omics technologies, and data-driven approaches that support vaccine design, immune profiling, and precision immunization strategies.

Vaccinology and Genomics | Pathogen Genomics | Host Genetics | Omics Technologies | Systems Vaccinology | Immune Profiling | Precision Vaccines | Genomic Data Analysis | Vaccine Discovery | Translational Research

Track 19: Clinical Vaccinology

This track focuses on the clinical evaluation, implementation, and real-world performance of vaccines. It covers clinical trial design, immunogenicity assessment, vaccine effectiveness, safety monitoring, and evidence-based strategies to optimize immunization programs.

Clinical Vaccinology | Vaccine Trials | Immunogenicity | Vaccine Effectiveness | Safety Monitoring | Real-World Evidence | Clinical Evaluation | Immunization Strategies | Evidence-Based Vaccines | Translational Research

Track 20: Post-Marketing Vaccine Safety

This track focuses on monitoring and evaluating vaccine safety after approval and widespread use. Topics include adverse event reporting, pharmacovigilance systems, risk assessment, real-world data analysis, and strategies to ensure ongoing vaccine safety and public confidence.

Post-Marketing Vaccine Safety | Pharmacovigilance | Adverse Event Monitoring | Risk Assessment | Safety Surveillance | Real-World Data | Vaccine Safety Evaluation | Post-Licensure Monitoring | Immunization Safety | Public Health Confidence

Participation Options

Vaccine Conference 2026 offers a range of participation opportunities, organized to accommodate academic, student, and industry participants:

1. Keynote & Oral Presentations: Share research and insights (25–50 min).
2. Workshops & Special Sessions: Interactive sessions with multiple presenters.
3. Symposia: In-depth discussions on key vaccine topics (45+ min).
4. Poster Presenters & Delegates: Present research and access all sessions.
5. Remote Attendance: Join virtually via live streaming or e-posters.
6. Exhibitors & Partners: Showcase products, technologies, or collaborate with the conference.

Benefits of Participation

Benefits for Speakers

1. Publication of all accepted abstracts in peer-reviewed journals.
2. CPD credits and official participation certificates.
3. Global visibility for research among leading experts in vaccinology, immunology, and public health.
4. Opportunities for professional growth and career advancement.
5. Access to the latest breakthroughs and innovations in vaccine research and development.
6. Build long-term collaborations through networking sessions.
7. Promote research via conference abstract books and materials.
8. Explore interdisciplinary topics including vaccine platforms, immunization strategies, and emerging infectious diseases.

Benefits for Delegates

1. Enhance knowledge and professional expertise in vaccine research, immunology, and public health.
2. Engage in scientific sessions and discussions that stimulate new ideas.
3. Explore innovative approaches to improve vaccine development, immunization coverage, and global health outcomes.
4. Network with leading researchers, clinicians, policymakers, and industry professionals.

Benefits for Sponsors

1. Increase brand visibility and recognition within the global vaccine and immunization sector.
2. Showcase products, technologies, and services to an international audience.
3. Generate high-quality leads and foster new business opportunities.
4. Build relationships with industry leaders and decision-makers.
5. Gain insights to refine strategies and benchmark against leading organizations.

Elite Sponsor Benefits

1. Sponsor 10 Poster Presentation Awards.
2. Three corporate-sponsored workshops with full audio-visual support.
3. Two complimentary exhibition booths (3×3 m) with priority location.
4. Four complimentary conference registrations.
5. Prominent logo display on the conference website and journal platforms.
6. One full-page color advertisement in the program or abstract book.
7. Three promotional inserts in delegate bags.
8. One post-conference email to registered attendees.
9. Online promotion across official social media channels.
10. 20% discount on sponsorship for the next year’s conference.

Gold Sponsor Benefits

1. Sponsor 5 Poster Presentation Awards.
2. Two corporate-sponsored workshops with catering and audio-visual support.
3. One complimentary exhibition booth (3×3 m) with priority location.
4. Three complimentary conference registrations.
5. Logo visibility on the conference website and sponsorship page.
6. One full-page color advertisement in the program or abstract book.
7. Two promotional inserts in delegate bags.
8. Online promotion across official social media channels.
9. 15% discount on next year’s sponsorship.

Silver Sponsor Benefits

1. Sponsor 3 Poster Presentation Awards.
2. Two complimentary conference registrations.
3. One corporate-sponsored workshop with catering and audio-visual support.
4. One complimentary exhibition booth (3×3 m) with priority location.
5. Logo display on the conference website sponsorship page.
6. One full-page color advertisement in the program or abstract book.
7. One promotional insert in delegate bags.
8. Priority access to additional sponsorship opportunities.
9. Online promotion across official social media channels.
10. 10% discount on next year’s sponsorship.

Market Analysis Report:

The global vaccine market in 2026 is projected to reach approximately USD 72–95 billion, with a CAGR of 6–10%. Growth is driven by advances in vaccine technologies such as mRNA, recombinant, and multivalent vaccines, as well as expanded immunization programs and efforts to address emerging infectious diseases. North America remains a leading market due to strong healthcare infrastructure and research capabilities, while Asia-Pacific shows rapid growth from increased manufacturing capacity and vaccine coverage. Opportunities include development of thermostable and combination vaccines, while challenges include cold chain logistics, supply constraints, and regional vaccine hesitancy.